-- The NEW Official Alizyme Thread! --

Dow Jones Newswires
12th December 2005

Alizyme's Drug Has Best-In-Class Potential

Numis says Alizyme's Cetilistat has the potential to be better than a "me-too" product as it demonstrated a superior side-effect profile, had a lower discontinuation rate as compared to both Xenical and placebo. Says if Cetilistat completes clinical development, it will likely become the best drug in its class. Says with a rather modest valuation the company could prove an attractive corporate target with 3 phase III-ready products in its portfolio. Keeps buy recommendation. Shares +8.1% at 146.70p.